Search

Your search keyword '"Agache, I"' showing total 849 results

Search Constraints

Start Over You searched for: Author "Agache, I" Remove constraint Author: "Agache, I"
849 results on '"Agache, I"'

Search Results

1. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

2. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

3. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

4. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

5. Correction to: Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

9. Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

10. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

11. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

12. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

13. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

16. The ARIA-MeDALL hypothesis

17. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

18. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

20. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project)

21. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products

23. Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

24. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

25. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

26. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

27. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

28. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app.

29. Climate change and global health: A call to more research and more action

30. Non‐allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

32. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study

33. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

34. Development and validation of combined symptom-medication scores for allergic rhinitis*

35. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

36. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

37. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

38. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

41. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

42. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

43. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

44. Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

46. Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic – An EAACI Position Paper

47. Childhood asthma outcomes during the COVID-19 pandemic:findings from the PeARL multinational cohort

48. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19

49. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

50. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Catalog

Books, media, physical & digital resources